Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
CA 2256124 C · Owner: C.B.F. Leti S.A. · Inventors: Requena Rolania, Jose Maria; Alonso Bedate, Carlos; Soto Alvarez, Manuel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described is a chimeric gene formed by the DNA sequences that encode antigenic determinants of four proteins of L. infantum useful for preventing or treating canine Leishmaniasis. The protein encoded by the chimeric gene contains one or more of the antigenic determinants of four proteins of L. infantum encoded by the chimeric gene. Also described as pharmaceutical compositions for the prevention and/or treatment of Leishmaniasis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1998 and granted June 16, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.